DavidMRindMD

Internal Medicine • Boston, MA

Assistant Clinical Professor of Medicine, Beth Israel Deaconess Medical Center

Join to view full profile

Are you Dr. Rind?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA 02215
Phone+1 617-667-2700

Fax+1 617-667-6405

Summary

Dr. David Rind, MD is a board certified internist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is an Assistant Clinical Professor of Medicine at Beth Israel Deaconess Medical Center.

Education & Training

UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1989
University of Rochester School of Medicine and DentistryClass of 1986

Certifications & Licensure

MA State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016

Publications & Presentations

PubMed

4 citations
Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.
Mrinmayee Joshi, Steven J Atlas, Molly Beinfeld, Richard H Chapman, David M Rind
Value in Health. 2023-06-01
4 citations
The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Co...
Dmitriy Nikitin, Anil N Makam, Kangho Suh, Avery McKenna, Josh J Carlson
Journal of Managed Care & Specialty Pharmacy. 2023-02-01
1 citations
The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia.
Victoria Lancaster, Marina Richardson, Francesca L Beaudoin, Patricia G Synnott, David M Rind
Journal of Managed Care & Specialty Pharmacy. 2022-11-01

Press Mentions

FDA Approves New Kind of Drug for SchizophreniaSeptember 28th, 2024
Is This COPD Treatment Out of Reach?August 20th, 2024
Ecstasy Drug Trials Missed Suicidal Thoughts of SubjectsAugust 12th, 2024
Join now to see all